Cytomegalovirus disease in immunocompetent adults.
Cytomegalovirus (CMV) is a highly prevalent and globally distributed virus. CMV infection in healthy adults is usually asymptomatic or causes a mild mononucleosis-like syndrome. CMV disease causes significant morbidity and mortality in neonates and severely immunocompromised adults. CMV disease can present with a wide range of manifestations, with colitis being the most common. The incidence of severe CMV disease in immunocompetent adults appears to be greater than previously thought, which may be partly due to immune dysfunction related to comorbidities such as kidney disease or diabetes mellitus. CMV disease can mimic an array of alternative diagnoses and pose a significant diagnostic challenge, especially in immunocompetent adults, leading to delayed diagnosis, adverse health outcomes and unnecessary financial expense. Non-invasive testing for CMV is widely available and can facilitate early diagnosis if used appropriately. Although limited, current evidence suggests that targeted antiviral therapy with ganciclovir or valganciclovir is appropriate for severe CMV disease in immunocompetent adults.
School of Medicine, University of Queensland, Brisbane, QLD, Australia. daniel.lancini@uqconnect.edu.au.
Daniel
D
Lancini
Australian Red Cross Blood Service, Brisbane, QLD, Australia.
Helen M
HM
Faddy
Australian Red Cross Blood Service, Brisbane, QLD, Australia.
Robert
R
Flower
Australian Red Cross Blood Service, Brisbane, QLD, Australia.
Chris
C
Hogan
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D015897:Comorbidity; D003586:Cytomegalovirus Infections / Q000175:diagnosis* / Q000453:epidemiology / Q000276:immunology*; D057210:Delayed Diagnosis; D015774:Ganciclovir / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007121:Immunocompetence; D000077562:Valganciclovir
D000998:Antiviral Agents; D000077562:Valganciclovir; D015774:Ganciclovir